Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

MicroRNAs in cardiovascular disease

Gurha, Priyatansh

Current Opinion in Cardiology: May 2016 - Volume 31 - Issue 3 - p 249–254
doi: 10.1097/HCO.0000000000000280
MOLECULAR GENETICS: Edited by Ali J. Marian
Buy

Purpose of review Noncoding RNAs regulate many aspects of cardiovascular biology and are potential therapy targets. In this review, we summarize and highlight current discoveries in the field of microRNAs, a class of noncoding RNAs.

Recent findings miRNAs regulate posttranscriptional gene expression and have been shown to control cardiac development, hypertrophy, fibrosis, and regeneration. Of note are the miRNAs that regulate cardiac contractility (for example, miR-25 and miR-22), cardiac regeneration (like miR-302–367 and miR99/100 families), and fibrosis (as miR-125b). Consistently with these roles of miRNAs, pharmacological intervention using anti-miRNA oligonucleotides (antagomirs or LNA-anti-miRs) has been shown to improve cardiac contractility and mitigate fibrosis, alleviating cardiac dysfunction in the setting of heart failure.

Summary miRNAs are crucial regulators of cardiac phenotype and have enthused both basic scientists and clinicians alike. With advancement of technology and better understanding of mechanisms governing miRNA deregulation, we are at the crossroads for deciphering miRNA function and modulating it for therapeutics.

Center for Cardiovascular Genetics, Houston, Texas, USA

Correspondence to Priyatansh Gurha, PhD, Center for Cardiovascular Genetics, 6770 Bertner Street, Suite C905, Houston, TX 77030, USA. Tel: +1 713 500 2335; e-mail: Priyatansh.gurha@uth.tmc.edu

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.